Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
Status:
Completed
Trial end date:
2021-07-21
Target enrollment:
Participant gender:
Summary
Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the
treatment of psoriasis.After single asending dose and mutiple asending dose in health
subjects. And the patients with moderate to severe plaque psoriasis will be randomized into 4
cohorts(15mg, 30mg, 60mg and placebo) approximately 216 subjects will be enrolled (52 for
each cohort ). This study includes an 16-week treatment Period, then a 36-week Treatment
Period without placebo.